National and Kapodistrian University of Athens
Νεφρίτιδα του συστηματικού ερυθηματώδους λύκου
Abstract
dc:descriptionThe benefits of cyclophosphamide, which has been the standard of care in the treatment of proliferative lupus nephritis for many years, have been limited by the significant drug-related toxicities. Therefore, aim of the international scientific community, especially in the last decade, is to induce remission with a short-course of cyclophosphamide and maintain the response with less toxic agents.The present work broadened the already existing information on the frequent and important in clinical practice issue of deciding the treatment for the maintenance of remission in proliferative lupus nephritis. Three studies assessed the efficacy and safety of mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis following a six-month induction course with intravenous pulses of cyclophosphamide, and compared to an historic control group receiveing long-term intravenous cyclophosphamide. The results come along with previous reports (Contreras et al. N Engl J Med, 2004).We showed that mycophenolate mofetil is at least as effective and safer than cyclophosphamide as maintenance therapy for proliferative lupus nephritis. Mycophenolate mofetil had beneficial effects in controlling the renal and extrarenal manifestations of the disease as well as maintaining remission in the majority of patients. Complete renal remission was observed in more than half of the patients. No chronic renal insufficiency and deaths as well as lifethreatening drug adverse events were observed in the study population. Compared to the long-term cyclophosphamide treatment, the achievement of complete renal remission was more often and a trend to less renal relapses was observed. Moreover, the short-course of cyclophosphamide as induction therapy was safe for the gonadal function, since even older women preserved menstruation during and after the completion of treatment in contrast to women who received long-term therapy with intravenous cyclophosphamide. We, finally, showed that tapering mycophenolate mofetil during maintenance treatment is not associated with increased risk of disease flare when ordered at least 1.5 year after the achievement of remission or complete renal remission.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Laskari, Katerina
- Λάσκαρη, Αικατερίνη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27527